FDA Alerts

Insulin Management
Insulin Management
07/29/2021
The US Food and Drug Administration has approved the first of its kind interchangeable biosimilar insulin product for the treatment of diabetes.
07/29/2021
Nutrition
Phil Lempert
Nutrition
07/08/2021
In this video, Phil Lempert discusses the recent US Food and Drug Administration approval of a new chronic weight management medication for adults with obesity or overweight.
07/08/2021
Chemotherapy
Chemotherapy
07/01/2021
The US Food and Drug Administration has approved a new asparaginase component for the treatment of a common pediatric and adult cancer.
07/01/2021
venous thromboembolism
venous thromboembolism
06/22/2021
The US Food and Drug Administration has approved the first oral option for the treatment of children aged 3 months to less than 12 years of age with venous thromboembolism following treatment with...
06/22/2021
Chronic Kidney Disease
Chronic Kidney Disease
06/21/2021
The US Food and Drug Administration has approved a new generic option for the control of serum phosphorus levels in patients with chronic kidney disease who are undergoing dialysis.
06/21/2021
Allergic Rhinitis
Allergic Rhinitis
06/18/2021
The FDA has approved a nasal antihistamine for nonprescription use in the treatment of seasonal and perennial allergic rhinitis in individuals aged 6 years and older.
06/18/2021
Pneumonia
Pneumonia
06/10/2021
The FDA has approved the first conjugate vaccine that protects against 20 Streptococcus pneumoniae serotypes in adults aged 18 years and older.
06/10/2021
Neurology
Neurology
06/07/2021
The accelerated approval pathway is used when a medication is found to provide a significant advantage over other approved treatments for serious or life-threatening conditions.
06/07/2021
Weight Loss
Weight Loss
06/07/2021
The US Food and Drug Administration has approved a drug for chronic weight management in adults with overweight or obesity and at least one weight-related condition.
06/07/2021
FDA
FDA
05/26/2021
The approval comes after positive results from the LIBERTY 1 and 2 studies were published, which showed safety and efficacy of the medication after 24 weeks.
05/26/2021